Author

J. Balmaña

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

BACKGROUND The randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib (oral poly-(ADP-ribose) polymerase [PARP] inhibitor) to placebo in 1,836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 (gBRCApv) germline variants and high-risk human epidermal growth factor receptor 2 (HER2...

J. Garber, D. Cameron, C. Campbell et al. · Annals of Oncology · 1 citation

Review Open access Sep 2026

Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success

Background Pharmacological cancer risk reduction has received far less investment than therapeutic oncology and only a few agents have entered routine practice. Understanding the predictors of positive outcomes of previous trials and issues faced is critical to future developments. Methods This systematic review (PROSP...

A. Xu-Vuillard, B. Duso, B. Arun et al. · ESMO Open · 0 citations